ATE238061T1 - Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten - Google Patents

Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Info

Publication number
ATE238061T1
ATE238061T1 AT98957605T AT98957605T ATE238061T1 AT E238061 T1 ATE238061 T1 AT E238061T1 AT 98957605 T AT98957605 T AT 98957605T AT 98957605 T AT98957605 T AT 98957605T AT E238061 T1 ATE238061 T1 AT E238061T1
Authority
AT
Austria
Prior art keywords
mitogens
cytokines
inhibition
immune responses
pathological immune
Prior art date
Application number
AT98957605T
Other languages
English (en)
Inventor
David Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE238061T1 publication Critical patent/ATE238061T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98957605T 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten ATE238061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
PCT/US1998/023584 WO1999025366A1 (en) 1997-11-05 1998-11-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number Publication Date
ATE238061T1 true ATE238061T1 (de) 2003-05-15

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957605T ATE238061T1 (de) 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Country Status (11)

Country Link
US (1) US6228359B1 (de)
EP (1) EP1028738B1 (de)
JP (1) JP4309047B2 (de)
AT (1) ATE238061T1 (de)
AU (1) AU747767B2 (de)
CA (1) CA2309115C (de)
DE (1) DE69813868T2 (de)
DK (1) DK1028738T3 (de)
ES (1) ES2198774T3 (de)
PT (1) PT1028738E (de)
WO (1) WO1999025366A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
DE69941113D1 (de) 1998-03-03 2009-08-27 Univ Southern California Zytokinen und mitogenen um "graft-versus-host disease" zu verhindern
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
ATE404662T1 (de) * 1999-05-05 2008-08-15 Univ Southern California Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
AU769243B2 (en) * 1999-09-01 2004-01-22 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
AU5340001A (en) 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
CN102971416B (zh) 2010-04-22 2018-03-30 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
EP2763692A2 (de) 2011-10-06 2014-08-13 European Molecular Biology Laboratory Verwendung von igf-1 in der modulation der treg-zellaktivität sowie behandlung und vorbeugung von autoimmunen erkrankungen oder störungen
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
US20150110738A1 (en) 2012-05-04 2015-04-23 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
JP2001523443A (ja) 2001-11-27
DK1028738T3 (da) 2003-08-11
WO1999025366A1 (en) 1999-05-27
PT1028738E (pt) 2003-08-29
EP1028738A1 (de) 2000-08-23
CA2309115A1 (en) 1999-05-27
CA2309115C (en) 2010-10-19
EP1028738B1 (de) 2003-04-23
JP4309047B2 (ja) 2009-08-05
AU1382799A (en) 1999-06-07
US6228359B1 (en) 2001-05-08
DE69813868D1 (de) 2003-05-28
AU747767B2 (en) 2002-05-23
DE69813868T2 (de) 2004-03-04
ES2198774T3 (es) 2004-02-01

Similar Documents

Publication Publication Date Title
ATE238061T1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
DE69929681D1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
DE69431473T2 (de) Inhibitor der stammzellproliferation und seine verwendung
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE190357T1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
DE69532813D1 (de) Inhibitor der stammzellenproliferation und dessen verwendung
MX9303127A (es) Metodo para reducir selectivamente la poblacion celular de leucocitos.
IT8121396A0 (it) Procedimento per il trattamento, in particolare per la rigenerazione di olio usato.
ATE53302T1 (de) Mittel zur behandlung von wunden.
ATE404662T1 (de) Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
DE69127713D1 (de) Behandlung von Abgasen, die Silikon- und/oder Phosphorverbindungen enthalten
Rachman Psychotherapy of difficult cases: Flexibility and responsiveness in contemporary practice.
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
DE3686019T2 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
DE69012883D1 (de) Methode für die Behandlung von Abgas.
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE261607T1 (de) Biozide mittel zur behandlung gewerblicher abwaesser, insbesondere gaswascherschlaemme.
EP1291020A3 (de) Verwendung von Zytokinen und Mitogenen fÜr Inhibierung von pathologischen Immunantworten
ATE230033T1 (de) Verwendung von primern für universelle fingerprint-analysen
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028738

Country of ref document: EP